Implementing population-level screening, brief intervention, and referral to treatment (SBIRT) for hazardous alcohol use in routine cancer care as a novel means of secondary cancer risk reduction
Active Grant Awarded
- Award ID
- R01CA308383
- Recipient
-
The University Of Kentucky Research Foundation UEI H1HYA8Z1NTM5
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $610,625
Award facts
- Assistance listing
- 93.393 Cancer Cause and Prevention Research
- Completion date 6% complete
- Place of performance
- Lexington, KY 40506, USA
Award details come from USAspending.gov.
About this award
The Department of Health and Human Services National Institutes of Health National Cancer Institute awarded The University of Kentucky Research Foundation $610,625 in obligated funding on August 5, 2026, under Assistance Listing 93.393, Cancer Cause and Prevention Research, for grant R01CA308383. The grant funds a pragmatic effectiveness trial that uses Zelen's method to randomize 1,200 head, neck, and esophageal cancer survivors to either MI-TRACS, a multilevel SBIRT intervention delivered as part of routine cancer care, or enhanced usual care (screening plus education). At the system level, MI-TRACS integrates automated and routine alcohol use screening, documentation, and treatment referrals into the electronic health record (EHR). At the clinician level, it provides training and EHR-integrated clinical decision-support tools. At the survivor level, it offers an EHR-integrated, evidence-based brief intervention with an optional referral. Place of performance is Lexington, Kentucky, with an ultimate completion date of July 31, 2031.
Michigan State University, doing business as Henry Ford Health+Michigan State University Health Sciences, received a sub-award dated September 25, 2026 (R01CA308383-3200007812-27-035). Its sub principal investigator provides expertise on technology-delivered alcohol reduction interventions, alcohol-related screening instruments and assessments, and usability testing. The sub principal investigator attends weekly study team meetings, oversees all aspects of the research alongside the PTE principal investigators, and works with the PTE IRB to set up reliance agreements ensuring sub-site research activities are IRB-compliant.
Description
- Abstract
- Alcohol use is the third leading preventable cause of cancer. Among cancer SURVIVORS, alcohol use increases the risk for both recurrence and development of new primary cancers. Despite this, nearly 80% of SURVIVORS, including those receiving cancer treatment, continue to drink alcohol, with 38% of drinkers doing so at hazardous levels. Alcohol-related cancer risk is not typically addressed in routine cancer care. Many oncology CLINICIANS report receiving inadequate training on how to address alcohol use during clinical encounters and state that current workflows do not enable alcohol-related intervention, necessitating the need to standardize and support delivery of routine, population-level alcohol screening and intervention among SURVIVORS in cancer care. To address this practice GAP, we propose a pragmatic effectiveness trial leveraging zelen's method to randomize 1,200 head, neck, and esophageal cancer SURVIVORS to either a multilevel screening, brief intervention, and referral to treatment (SBIRT) intervention, "MI-tracs" (multilevel intervention to track and reduce alcohol consumption among SURVIVORS), delivered as part of routine cancer care, or enhanced usual care (EUC; screening plus education). At the system-level, MI-tracs integrates automated and routine alcohol use screening, documentation, and treatment referrals within the electronic health record (EHR). At the clinician-level, IT provides clinician training and EHR-integrated clinical decision- support tools to facilitate SURVIVORS' treatment uptake and reinforce clinician knowledge and practice change related to alcohol-specific cancer risk. At the survivor-level, MI-tracs features an EHR-integrated, evidence- based brief intervention, tailored for SURVIVORS, with an optional referral for brief motivational interviewing (MI) sessions or, if indicated, addiction medicine treatment in a specialty clinic. We hypothesize that participation in MI-tracs will reduce hazardous alcohol use to a greater extent than EUC among SURVIVORS at high risk for alcohol-related problems. To increase uptake and overcome common challenges to SBIRT implementation in clinical settings (e.g., lack of fit and poor EHR integration), we will engage with multilevel partners to optimize MI-tracs delivery within the cancer clinic's workflow and ensure seamless integration with the EHR (aim 1). We will subsequently test MI-tracs' effectiveness (aim 2) and assess the primary outcome, reduction of hazardous alcohol use among high-risk SURVIVORS, via EHR data at 3 and 6 months after the initial screening, as well as MI-tracs' reach, adoption, implementation, and maintenance (aim 3) among SURVIVORS, CLINICIANS, and clinic staff. We will contextualize findings from the EHR (e.g., completion of the brief intervention (SURVIVORS) and use of the decision-support tools (CLINICIANS)) with survey and semi-structured interview data. All study activities will be guided by the practical, robust implementation and sustainability model (PRISM), an implementation science framework for use in both intervention planning and evaluation.
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| Michigan State University | $65,458 |
Quick answers
Who received award R01CA308383?
R01CA308383 was awarded to The University Of Kentucky Research Foundation by National Cancer Institute (National Institutes of Health) on August 5, 2026.
How much is award R01CA308383 worth?
$610,625 has been obligated on R01CA308383.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award